Cannabidiol (INN; acronym: CBD) is one of at least 113 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract.
CBD does not appear to have any intoxicating effects such as those caused by THC in marijuana, but may have effects on anxiety and an anti-psychotic effect
The Clinical Research
US National Library of Medicine National Institutes of Health records 8500 clinical trials focusing on CBD.
CBD is the major nonpsychoactive component of Cannabis sativa. According to a 2013 study published in the British Journal of Clinical Pharmacology, CBD benefits including acting in some experimental models as an anti-inflammatory, anticonvulsant, antioxidant, antiemetic, anxiolytic and antipsychotic agent, and is therefore a potential for neuroinflammation, epilepsy, oxidative injury, vomiting and nausea, anxiety and schizophrenia.
According to LEAFLY, a leading cannabis information service and consolidator of anecdotal evidence, CBD has shown the potential to help the following: